Farxiga Approval Expands Use to More Patients With Heart Failure

The Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death (CV), hospitalization for heart failure (HF), and urgent HF visit in adults with HF regardless of left ventricular ejection fraction (LVEF) status. Previously, the sodium-glucose cotransporter 2 (SGLT2) inhibitor had only been approved for HF patients with reduced ejection fraction (HFrEF).